Feb 10 2010
SafeStitch Medical, Inc. (OTCBB: SFES) announced today that it has
received CE Mark authorization to commercialize its AMID StaplerTM
in the European Economic Community. The new stapler is to be used for
fixation of mesh in the repair of hernia defects and also for the
approximation of tissues, including skin. The AMID Stapler™ is the first
surgical stapler designed specifically for use in inguinal hernia
repairs using the Lichtenstein method, in which mesh is implanted for
reinforcement. SafeStitch announced in November 2009 that it had
received 510(k) clearance from the Food and Drug Administration for sale
of the AMID StaplerTM in the U.S. market.
“The AMID StaplerTM is angled for safety and better
visibility and its patented mesh manipulators permit easy and safe mesh
placement. Its 17 box–shaped, sharp-tipped titanium staples are designed
specifically for this repair”
SafeStitch designed the stapler in collaboration with Dr. Parviz Amid, a
pioneer of and renowned expert in the Lichtenstein repair. Dr. Charles
J. Filipi, SafeStitch’s Medical Director and former President of the
American Hernia Society, noted that “approximately one million hernia
repairs are performed in the U.S. each year and the Lichtenstein repair
is used in as many as 70% of inguinal hernia repairs worldwide. Based on
clinical experience to date, we believe the AMID StaplerTM
will make the Lichtenstein repair faster and more attractive to surgeons
presently affixing mesh and closing incisions with sutures.”
“The AMID StaplerTM is angled for safety and better
visibility and its patented mesh manipulators permit easy and safe mesh
placement. Its 17 box–shaped, sharp-tipped titanium staples are designed
specifically for this repair,” explained Dr. Stewart Davis, SafeStitch’s
COO.
Jeffrey Spragens, SafeStitch’s President and CEO, noted that, “this CE
Mark and FDA clearance marks the completion of the development phase for
SafeStitch’s first four products: the SMART DilatorTM,
Standard BiteBlock, Airway BiteBlock and the AMID StaplerTM.
We continue our commercialization efforts for these products, starting
with the launch of the AMID StaplerTM. Our product
development efforts are now fully focused on SafeStitch’s minimally
invasive gastroplasty devices for obesity and GERD procedures. We have
successfully completed our pre-clinical laboratory studies with these
gastroplasty devices, and are preparing IDE applications for FDA
clearance to conduct multicenter clinical trials.”